All In MedTech

FDA Clearance Tracker · P050044-S021

VITAGEL SURGICAL HEMOSTAT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 11, 2013 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 11, 2013

Approved

Time to decision

715 days

Received Oct 27, 2011. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P050044-S021
Device name
VITAGEL SURGICAL HEMOSTAT
Applicant
Stryker Corp.
Applicant location
Kalamazoo, MI
Received
Oct 27, 2011
Decided
Oct 11, 2013
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P050044

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code LMF

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A NEW VERSION OF VITAGEL WHERE THE BOVINE THROMBIN COMPONENT IS REPLACED WITH RECOMBINANT HUMAN THROMBIN. THE PRODUCT, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME VITAGEL RT AND IS INDICATED IN SURGICAL PROCEDURES (OTHER THAN NEUROSURGICAL AND OPHTHALMIC) AS AN ADJUNCT TO HEMOSTASIS WHEN CONTROL OF BLEEDING BY LIGATURE OR CONVENTIONAL PROCEDURES IS INEFFECTIVE OR IMPRACTICAL.

Source documents

Other decisions for Stryker Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.